Of the known GSK‐3β inhibitors, lithium carbonate and tideglusib are the most intensively studied in clinical trials (Table 2), and these clinical trials were designed to evaluate the potential and anti‐AD properties of lithium carbonate and tideglusib as GSK‐3β inhibitors for AD prevention in older adults with mild cognitive impairment and at risk for dementia.122, 123. Here, GSK3B is linked to Alzheimer disease.